G. Peoples

S. Singletary, H. Kuerer, K. Hunt, 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

E. Mittendorf, G. Peoples, G. Clifton, 2010, Expert review of vaccines.

A peptidoglycan monomer with the glutamine to serine change and basic peptides bind in silico to TLR-2 (403–455)

R. Ramesh, P. Hwu, G. Peoples, 2011, Cancer Immunology, Immunotherapy.

Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.

E. Mittendorf, A. Philips, G. Peoples, 2018, Clinical immunology.

310 The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma

T. Wagner, G. Peoples, A. Berger, 2020, Journal for ImmunoTherapy of Cancer.

Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention.

G. Peoples, G. Clifton, T. Vreeland, 2022, Clinical immunology.

Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides

E. Mittendorf, C. Shriver, G. Peoples, 2005, Breast Cancer Research and Treatment.

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine

A. Stojadinovic, E. Mittendorf, G. Peoples, 2011, Cancer.

Clinical studies of vaccines targeting breast cancer.

H. Kuerer, J. Murray, G. Peoples, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role.

T. Eberlein, M. Klagsbrun, M. Freeman, 1995, Proceedings of the National Academy of Sciences of the United States of America.

CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells.

J. Richie, T. Eberlein, G. Peoples, 1993, Cellular immunology.

HER-2/neu Peptide Breast Cancer Vaccines: Current Status and Future Directions

E. Mittendorf, G. Peoples, 2007 .

Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

G. Peoples, D. Mcleod, C. Ioannides, 2005, Clinical Cancer Research.

Phase IClinical Trial of a HER-2 / neu Peptide ( E 75 ) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

G. Peoples, D. Mcleod, C. Ioannides, 2005 .

Clinical Studies of Vaccines Targeting Breast Cancer 1

H. Kuerer, J. Murray, G. Peoples, 2003 .

Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine

A. Stojadinovic, C. Shriver, G. Peoples, 2006, Cancer Immunology, Immunotherapy.

Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides.

J. Murray, G. Peoples, D. K. Kim, 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Cancer Vaccines for Solid Tumors

G. Peoples, T. Vreeland, Garth S Herbert, 2018 .

Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development

G. Peoples, D. Jackson, M. Hardin, 2017, Journal of Cancer.

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

T. Conrads, G. Peoples, K. Darcy, 2016, Oncotarget.

Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines

G. Peoples, J. Berry, T. Vreeland, 2016, Expert review of clinical immunology.

Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis

T. Wagner, G. Peoples, A. Berger, 2020, Cancer medicine.

Early results of a phase I clinical trial of an Ii-Key/Her2/neu MHC class II peptide-based vaccine in breast cancer patients.

J. Murray, C. Shriver, G. Peoples, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival

G. Peoples, G. Clifton, T. Vreeland, 2022, Annals of Surgical Oncology.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

J. Murray, E. Mittendorf, G. Peoples, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells.

Hui Gao, G. Peoples, S. Matsueda, 2009, Anticancer research.

Distinct patient responses to activation of T-cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccines.

Hui Gao, G. Peoples, S. Matsueda, 2009, Anticancer research.

Combat casualties in Afghanistan cared for by a single Forward Surgical Team during the initial phases of Operation Enduring Freedom.

G. Peoples, T. Gerlinger, R. Craig, 2005, Military medicine.

T cell receptor Vβ2 and Vβ6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer

T. Eberlein, G. Peoples, P. Goedegebuure, 1993 .

T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer.

T. Eberlein, G. Peoples, P. Goedegebuure, 1993, Journal of immunology.

An Educational Intervention Reduces Opioids Prescribed Following General Surgery Procedures.

G. Peoples, G. Clifton, C. Tzeng, 2020, The Journal of surgical research.

Feasibility of Breast Conservation Therapy in Metachronous or Synchronous Bilateral Breast Cancer

S. Singletary, M. Ross, F. Ames, 1999, Annals of Surgical Oncology.

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

G. Peoples, A. Berger, J. Sussman, 2021, Melanoma research.

Peptide Vaccine Strategies in the Treatment of Cancer

E. Mittendorf, G. Peoples, G. Clifton, 2013 .

Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement

G. Peoples, G. Clifton, T. Vreeland, 2020, Cancer Immunology, Immunotherapy.

Combat Wound Initiative program.

C. Attinger, S. Ahlers, P. Pasquina, 2010, Military medicine.

Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study.

Eric A Elster, Michael Pusch, Alexander Stojadinovic, 2007, The Journal of surgical research.

Oral calcium promotes pigment gallstone formation.

K. Lillemoe, H. Pitt, G. Peoples, 1989, The Journal of surgical research.

Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis.

S. Soker, M. Klagsbrun, M. Freeman, 1995, Cancer research.

The E75 HER2/neu peptide vaccine

E. Mittendorf, G. Peoples, S. Ponniah, 2008, Cancer Immunology, Immunotherapy.

Peptide-Based Cancer Vaccine Strategies and Clinical Results.

G. Peoples, G. Clifton, E. Schneble, 2016, Methods in molecular biology.

Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients

E. Mittendorf, G. Peoples, S. Ponniah, 2010, Cancer.

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

A. Stojadinovic, E. Mittendorf, G. Peoples, 2009, Clinical Cancer Research.

Caffeine prevents cholesterol gallstone formation.

K. Lillemoe, H. Pitt, G. Peoples, 1989, Surgery.

Therapeutic Cancer Vaccines for Melanoma

G. Peoples, G. Clifton, T. Vreeland, 2018 .

Novel dendritic cell-based vaccination in late stage melanoma

G. Peoples, Xianzhong Yu, E. Schneble, 2014, Human vaccines & immunotherapeutics.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence

J. Murray, E. Mittendorf, G. Peoples, 2016, Oncotarget.

Therapeutic Breast Cancer Vaccines

N. Ibrahim, J. Murray, G. Peoples, 2012, BioDrugs.

HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.

A. Gazdar, T. Eberlein, J. DiMaio, 1994, Cancer research.

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

J. Murray, E. Mittendorf, G. Peoples, 2020, Breast Cancer Research and Treatment.

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.

J. Murray, E. Mittendorf, G. Peoples, 2018, Clinical immunology.

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Dihua Yu, S. Reddy, E. Mittendorf, 2017, Cancer research.

Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

N. Ibrahim, E. Mittendorf, G. Peoples, 2017, Annals of Surgical Oncology.

Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients

A. Stojadinovic, E. Mittendorf, G. Peoples, 2012, Cancer.

Clinical Development of the E75 Vaccine in Breast Cancer

E. Mittendorf, G. Peoples, G. Clifton, 2016, Breast Care.

Preoperative Thyroid Ultrasound Is Indicated in Patients Undergoing Parathyroidectomy for Primary Hyperparathyroidism

Steven K. Libutti, Martha A. Zeiger, Alexander Stojadinovic, 2011, Journal of Cancer.

Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.

C. Shriver, G. Peoples, S. Ponniah, 2007, Oncology reports.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

H. Kohrt, J. Wolchok, L. Zitvogel, 2016, Journal of Immunotherapy for Cancer.

Overcoming Cancer Tolerance with Immune Checkpoint Blockade

E. Mittendorf, G. Peoples, G. Clifton, 2020, Cancer Immunology.

Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials

J. Murray, E. Mittendorf, G. Peoples, 2011, Expert review of vaccines.

Breast cancer vaccines

S. Singletary, E. Mittendorf, G. Peoples, 2007, Cancer.

Chemoprevention in familial adenomatous polyposis: past, present and future

G. Peoples, G. Clifton, C. Burke, 2020, Familial Cancer.

Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005

S. Devesa, E. Ron, A. Stojadinovic, 2009, Cancer Epidemiology Biomarkers & Prevention.

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

A. Stojadinovic, E. Mittendorf, G. Peoples, 2008, Cancer Immunology, Immunotherapy.

Surgical Quality and Nodal Ultrastaging Is Associated With Long-Term Disease-Free Survival in Early Colorectal Cancer: An Analysis of 2 International Multicenter Prospective Trials

M. McCarter, D. Elashoff, A. Stojadinovic, 2010, Annals of surgery.

Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials

A. Stojadinovic, G. Peoples, G. Clifton, 2023, Frontiers in Immunology.

Human tumor-infiltrating CD4+ T cells react to B cell lines expressing heat shock protein 70.

T. Eberlein, I. Yoshino, G. Peoples, 1994, Journal of immunology.

The Utility of a Rapid Parathyroid Assay for Uniglandular, Multiglandular, and Recurrent Parathyroid Disease

A. Stojadinovic, C. Shriver, G. Peoples, 2004, The American surgeon.

A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2

T. Wagner, G. Peoples, Xianzhong Yu, 2016, Cancer Immunology, Immunotherapy.

Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients

C. Shriver, G. Peoples, T. Kao, 2006, Clinical Cancer Research.

Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals.

J. Murray, G. Peoples, D. Gershenson, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.

E. Mittendorf, G. Peoples, G. Clifton, 2014, Immunotherapy.

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

C. Shriver, G. Peoples, C. Ioannides, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P17: Shock wave therapy for acute and chronic soft tissue wounds: A phase II trial

C. Attinger, E. Elster, A. Stojadinovic, 2007 .

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.

A. Stojadinovic, G. Peoples, G. Clifton, 2010, Vaccine.

Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine★

A. Stojadinovic, C. Shriver, G. Peoples, 2006, Breast Cancer Research and Treatment.

Cancer vaccines: should we be targeting patients with less aggressive disease?

E. Mittendorf, G. Peoples, G. Clifton, 2012, Expert review of vaccines.

Future Directions for Monitoring Treatment Responses in Breast Cancer

A. Stojadinovic, G. Peoples, Lindsey J. Graham, 2014, Journal of Cancer.

Cancer Incidence in the U.S. Military Population: Comparison with Rates from the SEER Program

K. McGlynn, S. Devesa, J. Potter, 2009, Cancer Epidemiology Biomarkers & Prevention.

Improving the outcomes of checkpoint inhibitors in breast cancer.

G. Peoples, 2019, The Lancet. Oncology.

The GP2 peptide: A HER2/neu‐based breast cancer vaccine

E. Mittendorf, G. Peoples, G. Clifton, 2012, Journal of surgical oncology.

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).

J. Murray, E. Mittendorf, G. Peoples, 2009, Expert opinion on biological therapy.

Optimal dose and schedule of an HER‐2/neu (E75) peptide vaccine to prevent breast cancer recurrence

A. Stojadinovic, E. Mittendorf, G. Peoples, 2008, Cancer.

Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.

J. Murray, E. Mittendorf, G. Peoples, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

E. Mittendorf, G. Peoples, C. Ioannides, 2008, Clinical Cancer Research.

Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial

T. Wagner, G. Peoples, A. Berger, 2022, Cancer Immunology, Immunotherapy.

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.

T. Wagner, G. Peoples, G. Clifton, 2016, Vaccine.

Abstract OT3-1-09: Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence

N. Ibrahim, G. Peoples, G. Clifton, 2015 .

Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.

J. Murray, A. Kudelka, J. Wharton, 1999, Clinical Cancer Research.

United States Military Cancer Institute Clinical Trials Group (USMCI GI-01) Randomized Controlled Trial Comparing Targeted Nodal Assessment and Ultrastaging With Standard Pathological Evaluation for Colon Cancer

A. Stojadinovic, A. Nissan, G. Peoples, 2012, Annals of surgery.

Prospective Randomized Study Comparing Sentinel Lymph Node Evaluation With Standard Pathologic Evaluation for the Staging of Colon Carcinoma: Results From the United States Military Cancer Institute Clinical Trials Group Study GI-01

J. Potter, A. Stojadinovic, A. Nissan, 2007, Annals of surgery.

Predictive Model of Outcome of Targeted Nodal Assessment in Colorectal Cancer

Alexander Stojadinovic, A. Stojadinovic, A. Nissan, 2010, Annals of surgery.

Alternative Perspective on the Rationale for Lymphatic Mapping for Sentinel Node Identification in Colon Cancer

A. Stojadinovic, A. Nissan, G. Peoples, 2008 .

HYOU1/Orp150 expression in breast cancer.

A. Stojadinovic, A. Nissan, C. Shriver, 2007, Medical science monitor : international medical journal of experimental and clinical research.

Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides

A. Kudelka, J. Wharton, G. Peoples, 1998, Annals of Surgical Oncology.

In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour.

T. Eberlein, I. Summerhayes, G. Peoples, 1995, Surgical oncology.

Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.

G. Peoples, G. Clifton, S. Ponniah, 2010, Journal of the American College of Surgeons.

Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients

J. Moul, C. Shriver, G. Peoples, 2004, Journal of Clinical Immunology.

Adjuvant HER2/neu peptide cancer vaccines in breast cancer.

E. Mittendorf, G. Peoples, G. Clifton, 2015, Immunotherapy.

Invariant chain-peptide fusion vaccine using HER-2/neu.

G. Peoples, S. Perez, M. Papamichail, 2014, Methods in molecular biology.

AE37: a novel T-cell-eliciting vaccine for breast cancer

E. Mittendorf, G. Peoples, S. Perez, 2011, Expert opinion on biological therapy.

Early results of a phase I clinical trial of an Ii-Key/Her2/neu MHC class II peptide-based vaccine in breast cancer patients

J. Murray, E. Mittendorf, C. Shriver, 2006 .

DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine

E. Mittendorf, G. Peoples, S. Perez, 2015, Journal of Immunotherapy for Cancer.

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines

E. Mittendorf, G. Peoples, G. Clifton, 2011, Expert review of vaccines.

AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence

G. Peoples, G. Clifton, T. Vreeland, 2020, Expert opinion on investigational drugs.

Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions

G. Peoples, A. Walker, G. Clifton, 2017, Expert review of clinical immunology.

Breast Cancer Immunotherapy.

G. Peoples, E. Schneble, D. Jinga, 2015, Maedica.

Rethinking cancer vaccines to avoid T-cell traps.

G. Peoples, 2013, Immunotherapy.

HER2/neu Vaccines in Breast Cancer

G. Peoples, S. Ponniah, S. Khoo, 2006, Women's health.

Prospective Trial Evaluating Electrical Impedance Scanning of Thyroid Nodules Before Thyroidectomy: Final Results

A. Stojadinovic, A. Nissan, S. Lenington, 2008, Annals of surgery.

Standardized pretreatment breast MRI—accuracy and influence on mastectomy decisions

G. Peoples, Kevin P. Banks, Aaron D. Kirkpatrick, 2011, Journal of surgical oncology.

Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer

Alexander Stojadinovic, A. Stojadinovic, A. Nissan, 2014, Journal of Cancer.

Time-Dependent Trends in Lymph Node Yield and Impact on Adjuvant Therapy Decisions in Colon Cancer Surgery: An International Multi-Institutional Study

M. McCarter, S. Steele, A. Stojadinovic, 2012, Annals of Surgical Oncology.

Current Approaches and Challenges in Early Detection of Breast Cancer Recurrence

Alexander Stojadinovic, Itzhak Avital, A. Stojadinovic, 2014, Journal of Cancer.

Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients

G. Peoples, S. Ponniah, M. Moroni, 2007, Cancer Immunology, Immunotherapy.

The most likely but largely ignored triggering factor for breast (or all) cancer invasion

B. Reva, Y. Hsiao, A. Stojadinovic, 2023, Journal of Cancer.

Results of a phase Ib trial of encapsulated rapamycin in prostate cancer patients under active surveillance to prevent progression.

G. Peoples, G. Clifton, M. Liss, 2020 .

Early definitive abdominal closure using serial closure technique on injured soldiers returning from Afghanistan and Iraq.

C. Shriver, G. Peoples, D. Kellicut, 2006, Journal of the American College of Surgeons.

Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

T. Conrads, G. Peoples, K. Darcy, 2019, Cancer medicine.

The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia after total or completion thyroidectomy.

A. Stojadinovic, C. Shriver, G. Peoples, 2006, Thyroid : official journal of the American Thyroid Association.

Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.

E. Mittendorf, G. Peoples, J. Litton, 2019, Journal of Clinical Oncology.

Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy.

E. Mittendorf, G. Peoples, S. Perez, 2014 .

Incidence rates of exocrine and endocrine pancreatic cancers in the United States

J. Potter, A. Stojadinovic, L. Enewold, 2010, Cancer Causes & Control.

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.

E. Mittendorf, A. Philips, G. Peoples, 2021, Clinical immunology.

Thyroid Cancer Incidence among Active Duty U.S. Military Personnel, 1990–2004

K. McGlynn, S. Devesa, J. Potter, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial.

E. Mittendorf, G. Peoples, J. Litton, 2019, Journal of Clinical Oncology.

Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

J. Murray, E. Mittendorf, G. Peoples, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer

S. Cantor, J. Skibber, G. Peoples, 2000, Diseases of the colon and rectum.

Classification of CD4+ T helper cell clones in human melanoma.

T. Eberlein, I. Yoshino, G. Peoples, 1994, Cellular immunology.

5-year qualitative results of isolated cryosurgical ablation for hepatic malignancy at Walter Reed Army Medical Center(1).

C. Shriver, G. Peoples, S. Rehrig, 2001, Current surgery.

Colorectal Prostate Skin Cancer Screening Among Hispanic White Non-Hispanic Men 2000–2005

J. Potter, S. Steele, A. Stojadinovic, 2011 .

Correlations between SerumMonocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity inBreastCancerPatients

C. Shriver, G. Peoples, T. Kao, 2006 .

Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.

T. Wagner, G. Peoples, G. Clifton, 2018, Immunotherapy.

The 274th Forward Surgical Team experience during Operation Enduring Freedom.

G. Peoples, T. Gerlinger, R. Craig, 2005, Military medicine.

Arming the Immune System Through Vaccination to Prevent Cancer Recurrence.

G. Peoples, T. Vreeland, D. Hale, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Arming the Immune System Through Vaccination to Prevent Cancer Recurrence.

G. Peoples, T. Vreeland, D. Hale, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

ASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination

G. Peoples, G. Clifton, T. Vreeland, 2021, Annals of Surgical Oncology.

Combined ClinicalTrial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute ClinicalTrials Group Study I-01and I-02

E. Mittendorf, G. Peoples, C. Ioannides, 2008 .

Immunomodulatory Effects of Interleukin‐12 on Human Tumor‐Infiltrating Lymphocytes

M. Bertagnolli, T. Eberlein, G. Peoples, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Cancer Vaccine Development Program collaborations.

G. Peoples, S. Ponniah, J. Holmes, 2010, Military Medicine.

Long-term follow-up assessment of a HER-2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients

E. Mittendorf, G. Peoples, D. Mcleod, 2008 .

Time-dependent Estimates of Recurrence and Survival in Colon Cancer: Clinical Decision Support System Tool Development for Adjuvant Therapy and Oncological Outcome Assessment

S. Steele, A. Stojadinovic, A. Nissan, 2014 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters.

G. Peoples, G. Clifton, T. Vreeland, 2023, Journal of surgical oncology.

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Dihua Yu, S. Reddy, E. Mittendorf, 2017, Cancer research.